Governments and pharmaceutical companies alike must work together in combating the ‘virus of intellectual property (IP) monopolies over COVID-19 vaccines – which  further exacerbates inequality and lack of access to vaccines for vulnerable groups.  That was the uptake of a group of experts speaking at a webinar Wednesday on “The Virus of IP Monopoly Capitalism”’ […] Continue reading ->
Delaying the second dose of the Pfizer/BioNTech COVID-19 vaccine by 12 weeks could generate antibody responses in those over the age of 80 more than threefold, found a pre-print study published on Friday. The study, conducted by the University of Birmingham and Public Health England, is the first to directly compare the immune response derived […] Continue reading ->
Limitations in COVID-19 testing capacity and surveillance—as well as uneven demand for testing—are likely masking the true severity of COVID-19 on the African continent, fueling the dangerous myth that much of Africa has been unscathed by COVID-19. Test positivity rates were above 10% across many African Union (AU) member states during the second wave—substantially higher […] Continue reading ->
In a far-reaching statement, WHO and the International Coalition of Medicines Regulatory Authorities (ICMRA) called on the pharma industry to provide much wider access to clinical data for all new medicines and vaccines approved, or under review, and even those that had been rejected.  “Clinical trial reports should be published without redaction of confidential information […] Continue reading ->